Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. [electronic resource]
Producer: 20030925Description: 481-6 p. digitalISSN:- 0340-7004
- Administration, Intravesical
- Aged
- Aged, 80 and over
- BCG Vaccine -- administration & dosage
- Biomarkers, Tumor -- urine
- Carcinoma in Situ -- drug therapy
- Case-Control Studies
- Cytokines -- urine
- Female
- Humans
- Immunotherapy
- Interleukin-2 -- urine
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- immunology
- Neoplasm Staging
- Prognosis
- Tumor Necrosis Factor-alpha -- urine
- Urinary Bladder Neoplasms -- drug therapy
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.